Costs vs. Outcomes for Patients With Type 2 Diabetes: The issue of cost in healthcare is a central point in the discussion of the future of medicine. While much is made of the cost of end-of-life care, many of the dollars spent yearly are focused on the treatment of chronic diseases like diabetes. The estimated yearly cost of diabetes care was $245 billion in the U.S. in 2012, the last year for which numbers have been reported. $50 billion of that was related to prescription drug purchases.Read More »
Battle between two GLP-1 receptor agonists proves semaglutide achieves favorable HbA1c levels, decreased mean body weight.Read More »
Non-adherence to Metformin Versus Therapeutic Failure: When is it Appropriate to Switch to Second-Line Therapies?
Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.Read More »
Patient specific considerations have to be taken into account prior to choosing GLP-1 agonist or SGLT2 inhibitor as second-line anti-hyperglycemic agent.Read More »
Patients projected to have increase in body mass index also likely to develop increased plasma glucose levels and have diminished insulin response.Read More »
Researchers use data from large ongoing cohort study to look for connection. In a recent study, researchers concluded that sugar and artificially sweetened beverage intake have been linked to cardiometabolic risk factors, which increase the risk of cerebrovascular disease and dementia. The study examined whether sugar or artificially sweetened beverage …Read More »
Part 1 of a four part series on a framework developed by Dr. Bradley Eilerman and Len Testa for recommending medications for treating patients with type 2 diabetes.
A thousand times today, in offices all over America, hospital patients will be diagnosed with type 2 diabetes. When that happens, a healthcare provider has to make a treatment decision of enormous complexity, often with partial information to go on, and in the span of just a few minutes.
How Does Empagliflozin Reduce Cardiovascular Mortality In Type 2 Patients, Including Those With PAD?
The answer comes from a mediation analysis of the EMPA-REG OUTCOME Trial.Read More »
Higher score measuring severity of pain indicated elevated treatment failure risk.Read More »
Young patients with low BMIs, C-peptide levels, and significant symptoms at onset of diabetes at higher risk of undergoing rapid C-peptide decline.Read More »